Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

So Young Yoo, Narayanasamy Badrinath, Hyun Young Woo, Jeong Heo

Journal: Mediators of inflammation 2018;2017():5198798

PMID: 28512387

Free Full Text on PubMed Central View on PubMed

Abstract

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

Address: BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.; Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea.; Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.

DOI: 10.1155/2017/5198798

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/livercancer.html

Other Literature Sources:

https://scite.ai/reports/28512387

MeSH Terms: Antineoplastic Agents, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Niacinamide, Oncolytic Virotherapy, Oncolytic Viruses, Phenylurea Compounds, Sorafenib